Tumores Mamários
Estudo randomizado de fase 2 | Eficácia do epigalocatecina-3-galato na prevenção de dermatites em pacientes com câncer de mama sob radioterapia pós-cirúrgica.
6 Jun, 2022 | 11:11hEfficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (gratuito por tempo limitado)
Resumo visual: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy
Análise de especialista | Cardiotoxicidade e campo em evolução do tratamento do câncer de mama direcionado ao HER2.
6 Jun, 2022 | 11:00hAtualização de diretriz ASCO | Terapia sistêmica para câncer de mama avançado positivo para receptor do fator de crescimento epidérmico humano 2.
2 Jun, 2022 | 13:53h
Comentário no Twitter
Out on JCO the latest @ASCO Guidelines Update on the treatment of HER2-positive ABC. Key points: standard first line remains THP, new second line is T-DXd, no standard after progression to T-DXd, a setting for which we urgently need data.https://t.co/2mMxBLACmf pic.twitter.com/2sXpzqz4ym
— Paolo Tarantino (@PTarantinoMD) June 1, 2022
Atualização de diretriz ASCO | Tratamento do câncer de mama avançado positivo para receptor do fator de crescimento epidérmico humano 2 e metástases cerebrais.
2 Jun, 2022 | 13:52h
Comentário no Twitter
🚨 Just published in #JCO: Guideline update on management of advanced human epidermal growth factor receptor 2–positive #breastcancer and #brainmetastases.
Read more ➡️ https://t.co/fz0lfJE8zb #bcsm #btsm #brainmets pic.twitter.com/C7tyCsVGR7
— Journal of Clinical Oncology (@JCO_ASCO) May 31, 2022
Redefinição dos subtipos de câncer de mama para orientar a priorização de tratamento e maximizar a resposta: biomarcadores preditivos em 10 terapias oncológicas.
1 Jun, 2022 | 13:27h
Comentário no Twitter
Online Now: Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies https://t.co/Im8F60VMjO
— Cancer Cell (@Cancer_Cell) May 27, 2022
Estudo randomizado | Efeito da radioterapia em posição supina vs. prona sobre os efeitos cutâneos tóxicos agudos em mulheres com mamas densas.
30 Mai, 2022 | 13:05hEffect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (gratuito por tempo limitado)
Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (gratuito por tempo limitado)
Comentário no Twitter
Adjuvant breast radiotherapy in the prone position decreases acute skin toxicity in women with large breast size, as demonstrated by this multicenter randomized clinical trial. https://t.co/6Emr2Hy5KH #BCSM #RadOnc
— JAMA Oncology (@JAMAOnc) May 26, 2022
Posicionamento científico | Implementação de teste para BRCA preventivo e preditivo em pacientes com cânceres de mama, ovário, pâncreas e próstata.
27 Mai, 2022 | 13:29hEstudo randomizado | Adição de metformina à terapia padrão não melhora os desfechos em pacientes com câncer de mama.
26 Mai, 2022 | 13:31hEffect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Who Will Benefit From Metformin? – JAMA Oncology
Comunicado de imprensa: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals – Lunenfeld-Tanenbaum Research Institute
Estudo randomizado | Everolimo não é benéfico quando adicionado à terapia endócrina adjuvante para pacientes com câncer de mama primário positivo para receptor de hormônio de alto risco e negativo para receptor 2 do fator de crescimento epidérmico humano.
26 Mai, 2022 | 12:53h
Comentários no Twitter
Previously presented @myESMO VP, the #UNIRAD RCT of adjuvant everolimus in high-risk EBC is now published on @JCO_ASCO. Trial stopped for futility: everolimus didn’t improve DFS & was poorly tolerated. Large research effort answering an important question.https://t.co/wmYLWpDWTC
— Paolo Tarantino (@PTarantinoMD) May 24, 2022
Everolimus added to adjuvant ET fails to improve DFS in patients with high-risk HR+ve, HER2 neg primary breast cancer; poorly tolerated -53.4% discontinuation ratehttps://t.co/lmq2jhbhCO
— K Pavithran (@drkpavithran) May 24, 2022
Estudo randomizado | Efeito do denosumabe adicionado a dois regimes diferentes com nab-paclitaxel como terapia neoadjuvante em pacientes com câncer de mama primário.
26 Mai, 2022 | 12:51hEffect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
In a randomized clinical trial in 780 pts with #breastcancer, addition of denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy with two different nab-paclitaxel schedules did not increase the pCR rate (41% vs 43% without denosumab): https://t.co/gPu6hrSp7z #bcsm
— NatureRevClinOncol (@NatRevClinOncol) May 24, 2022